Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial
Background - Non-nephrotoxic immunosuppressive strategies that allow reduction of calcineurin-inhibitor exposure without compromising safety or efficacy remain a goal in kidney transplantation. Immunosuppression based on the mammalian-target-of-rapamycin inhibitor everolimus was assessed as a strate...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
19 February 2011
|
| In: |
The lancet
Year: 2011, Jahrgang: 377, Heft: 9768, Pages: 837-847 |
| ISSN: | 1474-547X |
| DOI: | 10.1016/S0140-6736(10)62318-5 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/S0140-6736(10)62318-5 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0140673610623185 
|
| Verfasserangaben: | Klemens Budde, Thomas Becker, Wolfgang Arns, Claudia Sommerer, Petra Reinke, Ute Eisenberger, Stefan Kramer, Wolfgang Fischer, Harald Gschaidmeier, Frank Pietruck, on behalf of the ZEUS Study Investigators |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1807795853 | ||
| 003 | DE-627 | ||
| 005 | 20230426062334.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220624s2011 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S0140-6736(10)62318-5 |2 doi | |
| 035 | |a (DE-627)1807795853 | ||
| 035 | |a (DE-599)KXP1807795853 | ||
| 035 | |a (OCoLC)1341461577 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Budde, Klemens |e VerfasserIn |0 (DE-588)1111064571 |0 (DE-627)865478902 |0 (DE-576)475913329 |4 aut | |
| 245 | 1 | 0 | |a Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants |b an open-label, randomised, controlled trial |c Klemens Budde, Thomas Becker, Wolfgang Arns, Claudia Sommerer, Petra Reinke, Ute Eisenberger, Stefan Kramer, Wolfgang Fischer, Harald Gschaidmeier, Frank Pietruck, on behalf of the ZEUS Study Investigators |
| 264 | 1 | |c 19 February 2011 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 24.06.2022 | ||
| 520 | |a Background - Non-nephrotoxic immunosuppressive strategies that allow reduction of calcineurin-inhibitor exposure without compromising safety or efficacy remain a goal in kidney transplantation. Immunosuppression based on the mammalian-target-of-rapamycin inhibitor everolimus was assessed as a strategy for elimination of calcineurin-inhibitor exposure and optimisation of renal-graft function while maintaining efficacy. - Methods - In the ZEUS multicentre, open-label study, 503 patients (aged 18-65 years) who had received de-novo kidney transplants were enrolled. After initial treatment with ciclosporin, based on trough concentrations, and enteric-coated mycophenolate sodium (1440 mg/day, orally), corticosteroids (≥5 mg/day prednisolone or equivalent, orally), and basiliximab induction (20 mg, intravenously, on day 0 [2 h before transplantation], and on day 4), 300 (60%) patients were randomly assigned at 4·5 months in a 1:1 ratio to undergo calcineurin-inhibitor elimination (everolimus-based regimen that was based on trough concentrations [6-10 ng/mL] and enteric-coated mycophenolate sodium [1440 mg/day] with corticosteroids), or continue standard ciclosporin-based treatment. Randomisation was done by use of a central, validated system that automated the random assignment of treatment groups to randomisation numbers. The primary objective was to show better renal function (glomerular filtration rate [GFR]; Nankivell formula) with the calcineurin-inhibitor-free everolimus regimen at 12 months after transplantation. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00154310. - Findings - 118 (76%) of 155 everolimus-treated patients and 117 (81%) of 145 ciclosporin-treated patients completed treatment with study drug up to 12 months after transplantation. At this timepoint, the everolimus regimen was associated with a significant improvement in GFR versus the ciclosporin regimen (71·8 mL/min per 1·73 m2 vs 61·9 mL/min per 1·73 m2, respectively; mean difference 9·8 mL/min per 1·73 m2, 95% CI −12·2 to −7·5). Rates of biopsy-proven acute rejection were higher in the everolimus group than in the ciclosporin group after randomisation (15 [10%] of 154 vs five [3%] of 146; p=0·036), but similar for the full study period (23 [15%] vs 22 [15%]). Compared with the ciclosporin regimen, higher mean lipid concentrations, slightly increased urinary protein excretion, and lower haemoglobin concentrations were noted with the everolimus regimen; thrombocytopenia, aphthous stomatitis, and diarrhoea also occurred more often in the everolimus group. A higher incidence of hyperuricaemia was noted with ciclosporin. - Interpretation - Early elimination of calcineurin inhibitor by use of everolimus-based immunosuppression improved renal function at 12 months while maintaining efficacy and safety, indicating that this strategy may facilitate improved long-term outcomes in selected patients. - Funding - Novartis Pharma. | ||
| 700 | 1 | |a Becker, Thomas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Arns, Wolfgang |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sommerer, Claudia |d 1971- |e VerfasserIn |0 (DE-588)121857654 |0 (DE-627)705680002 |0 (DE-576)292921829 |4 aut | |
| 700 | 1 | |a Reinke, Petra |e VerfasserIn |4 aut | |
| 700 | 1 | |a Eisenberger, Ute |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kramer, Stefan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fischer, Wolfgang |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gschaidmeier, Harald |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pietruck, Frank |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The lancet |d London [u.a.] : Elsevier, 1823 |g 377(2011), 9768, Seite 837-847 |h Online-Ressource |w (DE-627)270128484 |w (DE-600)1476593-7 |w (DE-576)078590159 |x 1474-547X |7 nnas |a Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants an open-label, randomised, controlled trial |
| 773 | 1 | 8 | |g volume:377 |g year:2011 |g number:9768 |g pages:837-847 |g extent:11 |a Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants an open-label, randomised, controlled trial |
| 856 | 4 | 0 | |u https://doi.org/10.1016/S0140-6736(10)62318-5 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0140673610623185 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220624 | ||
| 993 | |a Article | ||
| 994 | |a 2011 | ||
| 998 | |g 121857654 |a Sommerer, Claudia |m 121857654:Sommerer, Claudia |d 50000 |e 50000PS121857654 |k 0/50000/ |p 4 | ||
| 999 | |a KXP-PPN1807795853 |e 4156288145 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1807795853","physDesc":[{"extent":"11 S."}],"name":{"displayForm":["Klemens Budde, Thomas Becker, Wolfgang Arns, Claudia Sommerer, Petra Reinke, Ute Eisenberger, Stefan Kramer, Wolfgang Fischer, Harald Gschaidmeier, Frank Pietruck, on behalf of the ZEUS Study Investigators"]},"id":{"doi":["10.1016/S0140-6736(10)62318-5"],"eki":["1807795853"]},"relHost":[{"id":{"zdb":["1476593-7"],"eki":["270128484"],"issn":["1474-547X"]},"physDesc":[{"extent":"Online-Ressource"}],"recId":"270128484","pubHistory":["1.1823 -"],"part":{"issue":"9768","text":"377(2011), 9768, Seite 837-847","pages":"837-847","year":"2011","volume":"377","extent":"11"},"title":[{"title_sort":"lancet","title":"The lancet"}],"origin":[{"dateIssuedKey":"1823","publisher":"Elsevier ; The Lancet Ltd.","dateIssuedDisp":"1823-","publisherPlace":"London [u.a.] ; London"}],"titleAlt":[{"title":"The lancet <London>"},{"title":"London lancet"},{"title":"Lancet (British ed. Online)"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"disp":"Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants an open-label, randomised, controlled trialThe lancet"}],"person":[{"display":"Budde, Klemens","family":"Budde","given":"Klemens","role":"aut"},{"role":"aut","given":"Thomas","family":"Becker","display":"Becker, Thomas"},{"role":"aut","given":"Wolfgang","family":"Arns","display":"Arns, Wolfgang"},{"given":"Claudia","role":"aut","display":"Sommerer, Claudia","family":"Sommerer"},{"display":"Reinke, Petra","family":"Reinke","given":"Petra","role":"aut"},{"role":"aut","given":"Ute","display":"Eisenberger, Ute","family":"Eisenberger"},{"family":"Kramer","display":"Kramer, Stefan","role":"aut","given":"Stefan"},{"role":"aut","given":"Wolfgang","display":"Fischer, Wolfgang","family":"Fischer"},{"family":"Gschaidmeier","display":"Gschaidmeier, Harald","given":"Harald","role":"aut"},{"family":"Pietruck","display":"Pietruck, Frank","role":"aut","given":"Frank"}],"language":["eng"],"note":["Gesehen am 24.06.2022"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedDisp":"19 February 2011","dateIssuedKey":"2011"}],"title":[{"title_sort":"Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants","subtitle":"an open-label, randomised, controlled trial","title":"Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants"}]} | ||
| SRT | |a BUDDEKLEMEEVEROLIMUS1920 | ||